Sector
PharmaceuticalsOpen
₹2,262.75Prev. Close
₹2,287.6Turnover(Lac.)
₹171.59Day's High
₹2,290Day's Low
₹2,25152 Week's High
₹2,54052 Week's Low
₹1,391Book Value
₹271.09Face Value
₹2Mkt Cap (₹ Cr.)
28,823.81P/E
36.22EPS
63.23Divi. Yield
2.2314 Jun 2024
12:00 AM
AGM
Announcement Date: 14 Jun, 2024
22 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
31 Jan 2024
12:00 AM
Dividend
Dividend Amount: 26
Record Date: 08 Feb, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 25.27 | 25.27 | 17.17 | 17.39 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,388.3 | 3,221.18 | 3,152.01 | 2,867.59 |
Net Worth | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 3,140.64 | 2,718.59 | 2,196.42 | 1,825.35 |
yoy growth (%) | 15.52 | 23.77 | 20.32 | 1.16 |
Raw materials | -832.56 | -730.08 | -663.97 | -399.29 |
As % of sales | 26.5 | 26.85 | 30.22 | 21.87 |
Employee costs | -585.87 | -498.11 | -437.82 | -342.89 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 900.54 | 902.09 | 616.59 | 562.44 |
Depreciation | -120.96 | -111.49 | -91.29 | -57.14 |
Tax paid | -180.68 | -226.45 | -171.54 | -134.92 |
Working capital | 278.87 | 306.22 | 272.08 | 231.17 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.52 | 23.77 | 20.32 | 1.16 |
Op profit growth | -2.83 | 72.09 | -2.56 | -13.8 |
EBIT growth | 0.07 | 45.27 | 11.19 | -12.34 |
Net profit growth | 6.54 | 53.16 | 3.18 | -14.46 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 4,208.71 | 3,742.64 | 3,340.99 | 2,889.69 | 2,587.87 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,208.71 | 3,742.64 | 3,340.99 | 2,889.69 | 2,587.87 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 84.6 | 98.64 | 115.68 | 25.98 | 92.19 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Mannalal B Agrawal
Vice Chairman
Madhusudan B Agrawal
Managing Director
Yogesh Agrawal
Independent Director
Chandrakanth M Khetan
Vice President & CS
Gaurang Shah
Joint Managing Director
Rajesh M Agrawal
Independent Director
K H Viswanathan
Independent Director
Prabhakar Dalal
Independent Director
Anjana Grewal
Independent Director
David Rasquinha
Independent Director
Medha Joshi
Independent Director
Simi Thapar
Independent Director
Rajesh Shashikant Dalal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ajanta Pharma Ltd
Summary
Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The companys business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharmas products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The companys institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Maurit
Read More
What is the Ajanta Pharma Ltd share price today?
The Ajanta Pharma Ltd shares price on N/A is Rs.₹2294.1 today.
What is the Market Cap of Ajanta Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ajanta Pharma Ltd is ₹28886.77 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Ajanta Pharma Ltd?
The PE and PB ratios of Ajanta Pharma Ltd is 36.22 and 8.45 as of 22 Jul ‘24
What is the 52 Week High and Low of Ajanta Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Ajanta Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ajanta Pharma Ltd is ₹1391 and ₹2531.95 as of 22 Jul ‘24
What is the CAGR of Ajanta Pharma Ltd?
Ajanta Pharma Ltd's CAGR for 5 Years at 29.83%, 3 Years at 17.12%, 1 Year at 63.21%, 6 Month at 4.20%, 3 Month at 10.03% and 1 Month at -3.42%.
What is the shareholding pattern of Ajanta Pharma Ltd?
The shareholding pattern of Ajanta Pharma Ltd is as follows:
Promoters - 66.27 %
Institutions - 25.79 %
Public - 7.94 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
